IARC attributes 2.3 million of 2024's new cancers to infections, about 260,000 of them to Epstein-Barr, a virus no vaccine yet prevents. Infections that current vaccines and antibiotics can already stop still cause far more of the total.
Perspective Coverage
4 publishers
- Builder
- Builder 25%
- Operator
- Operator 59%
- Investor
- Investor 16%
Reality
- Evidence72
- Adoption30
- Hype gap+8
- Incentives
- Not scored
- Confidence70
Long COVID's new suspect is a virus family no one had reason to count
A Nature cohort of 1,154 hospitalized patients ties lingering anellovirus activity to physical disability, which puts the sampling schedule, not the cytokine panel, at the center of trial design.
Reality
- Evidence64
- Adoption
- Not scored
- Hype gap+18
- Incentives38
- Confidence58
Decades of static data, collected without the controls that turned out to matter
Reporting from the June meeting of the Electrostatics Society of America says the field's own findings make earlier static research look unreliable. The note names no variable and no magnitude.
Reality
- Evidence20
- Adoption
- Not scored
- Hype gap+38
- Incentives58
- Confidence30
The everything virus: Epstein-Barr's disease ledger is now big enough to price a vaccine
Epstein-Barr infects about 95 percent of people and causes roughly 2 percent of cancers worldwide. It is also now tied to multiple sclerosis, with no approved vaccine and no antiviral to test the link.
Reality
- Evidence48
- Adoption8
- Hype gap+24
- Incentives40
- Confidence52
COVID reactivates 11 sleeping viruses, and an obscure one tracks with long COVID disability
A Nature study of 1,154 hospitalized patients links Anelloviridae reactivation to lasting physical disability, which gives post-viral clinics something to measure instead of a syndrome of exclusion.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+28
- Incentives65
- Confidence52